騰盛博藥-B(02137.HK)被納入MSCI中國小型股指數成為成份股
格隆匯5月25日丨騰盛博藥-B(02137.HK)發佈公吿,公司將被納入MSCI中國小型股指數成為成份股,於2022年5月31日收市後生效。
公司首席財務官兼戰略官李安康博士表示:“成為MSCI中國小型股指數的成分股,是繼去年我們被納入恆生綜合指數和深港通後,本公司在資本市場上的又一個重要里程碑。作為少數被納入全球資本市場中最具影響力的以中國為重點的指數之一的生物技術股票,其表明了我們的知名度和全球投資者的認可度在不斷提高。我們期待通過為全球具有重大未被滿足的醫療需求,和具有巨大公共衞生負擔的疾病開發創新療法,以繼續為股東創造價值。”
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.